Biotech and Pharma

India's Ranbaxy issues massive recall of generic Lipitor

India-based generic drugmaker Ranbaxy Laboratories has issued a recall of generic versions of the cholesterol drug Lipitor in the U.S. because of potential dosage issues, The Wall Street Journal reported Friday.

Ranbaxy Laboratories' atorvastatin calcium tablets
Dhiraj Singh | Bloomberg | Getty Images

The company recalled more than 64,000 bottles of 10-milligram tablets of atorvastatin calcium—the active ingredient in Lipitor—saying some bottles could possibly contain a higher dose, the U.S. Food and Drug Administration said in a note.

Ranbaxy confirmed the recall on Friday, noting that the recall started in mid-January. Notice of the recall was posted on the FDA's website this week.

The company, which makes ingredients for drugs used in oncology, dermatology, gastrointestinal and cardiovascular disorders, generated 36 percent of its sales in the U.S. in the quarter ended in December.

Last month, Ranbaxy suspended shipments of pharmaceutical ingredients from two plants amid growing scrutiny of its manufacturing processes by regulators.

The suspension affected supplies to other key markets such as Europe and India, two people with direct knowledge of the matter said.

Click here to read the full report from WSJ.

—By CNBC with Reuters.